Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lerut, T.
Right arrow Articles by Decker, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lerut, T.
Right arrow Articles by Decker, G.
(Chest. 1999;116:463S-465S.)
© 1999 American College of Chest Physicians

Treatment of Esophageal Carcinoma*

Toni Lerut, MD, FCCP, MD, PhD; Willy Coosemans, MD, PhD; Paul De Leyn, MD, PhD; Dirk Van Raemdonck, MD, FCCP; George Deneffe, MD and George Decker, MD

* From the Department Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium.

Correspondence to: Tony Lerut, Department of Thoracic Surgery, University Hospital Gasthuisberg, Herestraat 49, Leuven, Belgium 3000

Cancer of the esophagus and gastroesophageal junction remains a virulent malignancy with an overall poor prognosis. Especially in the Western hemisphere, the incidence of adenocarcinoma is sharply rising. Over the last two decades, surgery has become the mainstay of treatment. Decreased surgical mortality and standardization of oncologic principles focusing on the completeness of resection are believed to be responsible for the improved 5-year survival rates, which are reaching >= 30%. Until now, there has been no proven benefit from combined neoadjuvant treatment modalities using chemotherapy or chemoradiotherapy except for the subset of patients showing a complete response at pathologic examination. Further research should focus on new chemotherapeutic agents and the development of molecular markers that allow better identification of candidates for multimodality regimens.




This article has been cited by other articles:


Home page
 JCOHome page
X. Wu, J. Gu, T.-T. Wu, S. G. Swisher, Z. Liao, A. M. Correa, J. Liu, C. J. Etzel, C. I. Amos, M. Huang, et al.
Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer
J. Clin. Oncol., August 10, 2006; 24(23): 3789 - 3798.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K S Nair, R Naidoo, and R Chetty
Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value
J. Clin. Pathol., April 1, 2005; 58(4): 343 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
S. Mattioli, F. D'Ovidio, P. Tazzari, V. Pilotti, N. Daddi, G. Bandini, M. Piccioli, and S. Pileri
Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer
Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 576 - 579.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.